Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins.
Yamaguchi-Sasaki T, Tokura S, Ogata Y, Kawaguchi T, Sugaya Y, Takahashi R, Iwakiri K, Abe-Kumasaka T, Yoshida I, Arikawa K, Sugiyama H, Kanuma K.
A novel series of macrocyclic pyrazolo[1,5-<i>a</i>]pyrimidine derivatives as respiratory syncytial virus (RSV) fusion glycoprotein (F protein) inhibitors were designed and synthesized based on docking studies of acyclic inhibitors. This effort resulted in the discovery of several macrocyclic compounds, such as <b>12b</b>, <b>12f</b>, and <b>12h</b>, with low nanomolar to subnanomolar activities against the wild-type RSV F protein A2. In addition, <b>12h</b> showed a single-digit nanomolar potency against the previously reported drug-resistant mutant D486N. Molecular modeling and computational analyses suggested that <b>12h</b> binds to the D486N mutant while maintaining a rigid bioactive conformation via macrocyclization and that it interacts with a hydrophobic cavity of the mutant using a new interaction surface of <b>12h</b>. This report describes the rational design of macrocyclic compounds with dual inhibitory activities against wild-type and mutant RSV F proteins.